Advertisement
ABBV vs MRK
Which Stock Would AI Choose? AbbVie (ABBV) vs. Merck (MRK) Stock Comparison
Key Takeaways
- ABBV has delivered solid year-to-date returns of approximately 16% amid strong performance in immunology products like Skyrizi and Rinvoq.
- MRK has outperformed with year-to-date gains near 26% and one-year returns exceeding 60%, driven by Keytruda momentum and recent pipeline advancements.
- Both companies operate in the biopharmaceutical sector with diversified portfolios, though MRK shows greater emphasis on oncology and vaccines while ABBV maintains leadership in immunology and aesthetics.
- Recent market activity highlights MRK benefiting from multiple positive regulatory and trial updates, including new product approvals.
- ABBV faces near-term earnings scrutiny alongside a noted pipeline trial clarification, yet maintains robust overall financial positioning.
- Relative performance favors MRK in recent weeks on momentum and catalyst flow, while both exhibit defensive sector characteristics.
Introduction
This comparison examines ABBV (AbbVie Inc.) and MRK (Merck & Co., Inc.), two established players in the biopharmaceutical industry. Investors and traders focused on healthcare sector exposure, dividend stability, and growth from innovative therapies may find the analysis relevant. The review centers on observable recent market behavior, business fundamentals, and positioning within a competitive landscape marked by patent dynamics and pipeline developments.
AbbVie Overview and Recent Performance
AbbVie Inc. is a research-based biopharmaceutical company with key franchises in immunology, oncology, aesthetics, and neuroscience. Its portfolio includes Skyrizi and Rinvoq for autoimmune conditions, alongside Botox and other aesthetic products. In recent market activity, ABBV shares have shown resilience, trading near the upper end of their 52-week range with a closing price of 259.36 on July 24, 2026. Year-to-date performance stands at approximately 16%, supported by sustained demand for core immunology therapies. Recent developments include clarification on a Phase 3 trial for epcoritamab in diffuse large B-cell lymphoma, alongside anticipation of upcoming quarterly results expected to reflect earnings growth. Sentiment has remained constructive amid broader sector rotation toward defensive healthcare names.
Merck Overview and Recent Performance
Merck & Co., Inc. focuses on oncology, vaccines, and infectious diseases, with Keytruda as its flagship immunotherapy asset. The company also maintains a substantial animal health business. In recent market activity, MRK shares closed at 131.07 on July 24, 2026, reflecting year-to-date gains of about 26% and one-year total returns near 61%. Performance has been bolstered by positive updates on HIV prevention programs, regulatory approvals such as the first oral PCSK9 inhibitor, and ongoing Keytruda combination data. Multiple analyst target increases in recent weeks have reinforced positioning. Sentiment reflects strength from pipeline catalysts and diversified revenue streams, though investor attention remains on long-term Keytruda lifecycle management.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots optimized for prevailing market conditions. Tickeron offers hundreds of AI Trading Bots capable of trading thousands of different tickers across equities, with varying strategies, timeframes, risk parameters, and historical performance statistics. Only those demonstrating strong adaptability, consistent metrics, and relevance to current trends appear in the Trending section. Available bots cover a wide range of styles and deliver diverse statistics on win rates, drawdowns, and returns. This resource provides traders with transparent data on bot suitability. Explore the full selection at Trending AI Robots.
Head-to-Head Comparison
ABBV and MRK both generate substantial revenue from patent-protected therapies but differ in emphasis. ABBV derives significant growth from immunology assets with combined sales projections exceeding prior benchmarks, complemented by aesthetics exposure. MRK centers on oncology leadership via Keytruda while expanding in vaccines and HIV. Recent momentum has favored MRK through a higher volume of positive regulatory and trial news. Risk factors include portfolio concentration for both, with MRK noting Keytruda dependency concerns and ABBV managing biosimilar competition in legacy products. Sector exposure remains similar within healthcare, though market sentiment in recent weeks has tilted toward MRK on relative outperformance and catalyst density.
Tickeron AI Verdict
Based on observable factors including stronger recent trend consistency, elevated year-to-date and one-year returns, and a denser flow of positive pipeline and regulatory developments, Tickeron’s AI would currently assign a higher probabilistic preference to MRK over ABBV in a comparative framework. Stability metrics and relative positioning support this tilt, though both stocks exhibit defensive qualities suited to varied market environments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a StrongBuy and MRK is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 3 FA rating(s) are green whileMRK’s FA Score has 2 green FA rating(s).
- ABBV’s FA Score: 3 green, 2 red.
- MRK’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 4 TA indicator(s) are bullish while MRK’s TA Score has 4 bullish TA indicator(s).
- ABBV’s TA Score: 4 bullish, 3 bearish.
- MRK’s TA Score: 4 bullish, 4 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +2.85% price change this week, while MRK (@Pharmaceuticals: Major) price change was +5.59% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.25%. For the same industry, the average monthly price growth was +0.27%, and the average quarterly price growth was +2.34%.
Reported Earning Dates
ABBV is expected to report earnings on Oct 23, 2026.
MRK is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.25% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| ABBV | MRK | ABBV / MRK | |
| Capitalization | 441B | 335B | 132% |
| EBITDA | 16.9B | 19.4B | 87% |
| Gain YTD | 12.368 | 30.663 | 40% |
| P/E Ratio | 70.47 | 108.67 | 65% |
| Revenue | 62.8B | 65.8B | 95% |
| Total Cash | N/A | N/A | - |
| Total Debt | 72.9B | 49.1B | 148% |
ABBV | MRK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 28 | 42 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 39 Fair valued | 57 Fair valued | |
PROFIT vs RISK RATING 1..100 | 6 | 41 | |
SMR RATING 1..100 | 1 | 47 | |
PRICE GROWTH RATING 1..100 | 31 | 14 | |
P/E GROWTH RATING 1..100 | 79 | 2 | |
SEASONALITY SCORE 1..100 | 47 | 65 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABBV's Valuation (39) in the Pharmaceuticals Major industry is in the same range as MRK (57). This means that ABBV’s stock grew similarly to MRK’s over the last 12 months.
ABBV's Profit vs Risk Rating (6) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (41). This means that ABBV’s stock grew somewhat faster than MRK’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (47). This means that ABBV’s stock grew somewhat faster than MRK’s over the last 12 months.
MRK's Price Growth Rating (14) in the Pharmaceuticals Major industry is in the same range as ABBV (31). This means that MRK’s stock grew similarly to ABBV’s over the last 12 months.
MRK's P/E Growth Rating (2) in the Pharmaceuticals Major industry is significantly better than the same rating for ABBV (79). This means that MRK’s stock grew significantly faster than ABBV’s over the last 12 months.
| ABBV | MRK | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 51% |
| Stochastic ODDS (%) | 2 days ago 69% | 2 days ago 52% |
| Momentum ODDS (%) | 2 days ago 40% | 2 days ago 56% |
| MACD ODDS (%) | 2 days ago 51% | 2 days ago 62% |
| TrendWeek ODDS (%) | 2 days ago 63% | 2 days ago 57% |
| TrendMonth ODDS (%) | 2 days ago 65% | 2 days ago 56% |
| Advances ODDS (%) | 4 days ago 60% | 2 days ago 56% |
| Declines ODDS (%) | 11 days ago 48% | 16 days ago 51% |
| BollingerBands ODDS (%) | 2 days ago 63% | 2 days ago 40% |
| Aroon ODDS (%) | 2 days ago 61% | 2 days ago 62% |
Advertisement
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with NVS. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then NVS could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | +0.83% | ||
| NVS - ABBV | 51% Loosely correlated | -0.39% | ||
| BMY - ABBV | 49% Loosely correlated | +1.49% | ||
| JNJ - ABBV | 47% Loosely correlated | +0.47% | ||
| MRK - ABBV | 46% Loosely correlated | +1.98% | ||
| AMGN - ABBV | 46% Loosely correlated | +0.40% | ||
More | ||||
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with NVS. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then NVS could also see price increases.